Compare Rocket Lab USA Inc (RKLB) vs Zoetis Inc (ZTS) Price & Performance

Rocket Lab (RKLB) trades at $68.40, down 4.89% today, amid bearish technical signals despite positive business developments. The company recently secured its largest-ever commercial Electron launch contract with Synspective for 20 missions, expanding its backlog to over 100 launches. Fundamentally, RKLB shows strong revenue growth with $602 million in 2025 and projected $769 million in 2026, though it remains unprofitable with negative margins. Analyst sentiment remains overwhelmingly bullish with 16 buy ratings and a $107 consensus price target, representing significant upside potential from current levels.

Rocket Lab presents a high-risk, high-reward opportunity with substantial growth potential in the expanding space economy offset by persistent losses and competitive threats from SpaceX. The company's expanding launch backlog and Neutron rocket development provide long-term catalysts, but investors must weigh the premium valuation against ongoing cash burn and execution risks in a capital-intensive industry.

Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.

The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.